认知与衰老项目（CAP）——推进阿尔茨海默病临床前治疗评估
CAP--advancing the evaluation of preclinical Alzheimer disease treatments.
作者信息
Reiman Eric M, Langbaum Jessica B, Tariot Pierre N, Lopera Francisco, Bateman Randall J, Morris John C, Sperling Reisa A, Aisen Paul S, Roses Allen D, Welsh-Bohmer Kathleen A, Carrillo Maria C, Weninger Stacie
机构信息
Banner Alzheimer's Institute, 901 E. Willetta Street, Phoenix, AZ 85006, USA.
Grupo de Neurosciencias, Universidad de Antioquia, Calle 62 #52-59, Medellin, Colombia.
出版信息
Nat Rev Neurol. 2016 Jan;12(1):56-61. doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29.
Abstract
If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the initiation and performance of preclinical AD trials. In this article, we note some of the current challenges, opportunities and emerging strategies in preclinical AD treatment. We describe the Collaboration for Alzheimer's Prevention (CAP)-a convening, harmonizing and consensus-building initiative to help stakeholders advance AD prevention research with rigour, care and maximal impact-and we demonstrate the impact of CAP on the goals and design of new preclinical AD trials.
摘要
如果我们要找到能够延缓、降低风险或完全预防阿尔茨海默病（AD）临床发病的治疗方法，我们就需要更快的方法来评估有前景的临床前AD治疗方案，需要新的合作方式以支持共同目标，还需要有决心加快临床前AD试验的启动和实施。在本文中，我们指出了临床前AD治疗当前面临的一些挑战、机遇和新兴策略。我们介绍了阿尔茨海默病预防协作组织（CAP）——一项召集各方、协调一致并建立共识的倡议，旨在帮助利益相关者严谨、审慎且高效地推进AD预防研究——并且我们展示了CAP对新的临床前AD试验的目标和设计所产生的影响。
相似文献
1
CAP--advancing the evaluation of preclinical Alzheimer disease treatments.
Nat Rev Neurol. 2016 Jan;12(1):56-61. doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29.
2
Clinical trials in predementia stages of Alzheimer disease.
Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22.
3
Subjective Cognitive Decline in Preclinical Alzheimer's Disease.
Annu Rev Clin Psychol. 2017 May 8;13:369-396. doi: 10.1146/annurev-clinpsy-032816-045136.
4
Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment.
Geriatrics. 2007 Apr;62(4):19-23.
5
Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.
J Clin Psychiatry. 2016 Dec;77(12):e1631-e1638. doi: 10.4088/JCP.15m10413.
6
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007.
7
Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome.
Alzheimers Dement. 2019 Feb;15(2):245-257. doi: 10.1016/j.jalz.2018.08.009. Epub 2018 Nov 28.
8
In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
Neuroimage. 2017 Mar 1;148:296-304. doi: 10.1016/j.neuroimage.2016.12.026. Epub 2016 Dec 15.
9
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Neuropharmacology. 2016 Sep;108:128-35. doi: 10.1016/j.neuropharm.2016.02.005. Epub 2016 Feb 10.
10
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
J Alzheimers Dis. 2015;47(1):231-42. doi: 10.3233/JAD-150128.
引用本文的文献
1
Resting-state functional magnetic resonance imaging in a randomized clinical trial for Alzheimer's disease.
Neuroimage Rep. 2021 Sep 24;1(4):100055. doi: 10.1016/j.ynirp.2021.100055. eCollection 2021 Dec.
2
15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN.
medRxiv. 2024 Aug 9:2024.08.08.24311689. doi: 10.1101/2024.08.08.24311689.
3
Plasma β-microglobulin and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: the CABLE study.
Alzheimers Res Ther. 2023 Apr 1;15(1):69. doi: 10.1186/s13195-023-01217-6.
4
Preclinical Alzheimer's dementia: a useful concept or another dead end?
Eur J Ageing. 2022 Oct 19;19(4):997-1004. doi: 10.1007/s10433-022-00735-w. eCollection 2022 Dec.
5
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial.
Alzheimers Dement. 2023 May;19(5):1938-1946. doi: 10.1002/alz.12843. Epub 2022 Nov 14.
6
Planning for Prevention of Parkinson Disease: Now Is the Time.
Neurology. 2022 Aug 16;99(7 Suppl 1):1-9. doi: 10.1212/WNL.0000000000200789.
7
Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study.
Biomedicines. 2022 Apr 30;10(5):1045. doi: 10.3390/biomedicines10051045.
8
ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics.
Front Neurol. 2022 Feb 9;13:826423. doi: 10.3389/fneur.2022.826423. eCollection 2022.
9
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.
Alzheimers Dement. 2022 Dec;18(12):2687-2698. doi: 10.1002/alz.12624. Epub 2022 Feb 24.
10
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
JAMA Neurol. 2022 Mar 1;79(3):228-243. doi: 10.1001/jamaneurol.2021.5216.
本文引用的文献
1
Arizona Alzheimer's Registry: Strategy and Outcomes of a Statewide Research Recruitment Registry.
J Prev Alzheimers Dis. 2014 Sep;1(2):74-79. doi: 10.14283/jpad.2014.1.
2
A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.
Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12.
3
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.
JAMA Neurol. 2015 Mar;72(3):316-24. doi: 10.1001/jamaneurol.2014.3314.
4
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
JAMA Neurol. 2014 Aug;71(8):961-70. doi: 10.1001/jamaneurol.2014.803.
5
The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
J Clin Psychiatry. 2014 Jun;75(6):652-60. doi: 10.4088/JCP.13m08927.
6
An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.
Alzheimers Dement. 2014 Nov;10(6):666-74. doi: 10.1016/j.jalz.2014.02.002. Epub 2014 Apr 21.
7
The A4 study: stopping AD before symptoms begin?
Sci Transl Med. 2014 Mar 19;6(228):228fs13. doi: 10.1126/scitranslmed.3007941.
8
New applications of disease genetics and pharmacogenetics to drug development.
Curr Opin Pharmacol. 2014 Feb;14:81-9. doi: 10.1016/j.coph.2013.12.002. Epub 2014 Jan 3.
9
Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial.
JAMA Intern Med. 2014 Mar;174(3):324-33. doi: 10.1001/jamainternmed.2013.13656.
10
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889.
Zotero 插件